AUTH/2540/11/12 & AUTH/2545/11/12: Diabetes meeting alleged to be ‘education’ but actually promotion (No breach)

No breach of the ABPI Code (2012). An anonymous, non-contactable clinician complained that a jointly run diabetes meeting was presented as education but was actually promotional. The Panel ruled no breach of Clauses 9.1, 12.1, 19.1 and 19.3.

What happened

• An anonymous clinician complained about a meeting held jointly by Eli Lilly and Boehringer Ingelheim (via their “Diabetes Alliance”).
• The meeting topic was “Complexity of type 2 diabetes, a hands-on guide to simplifying care in clinical practice” and was part of a UK-wide series.
• The complainant alleged the event was advertised as genuine medical education but overtly promoted Trajenta (linagliptin) and Byetta (exenatide).
• The complainant alleged speakers were “paid sales people”, a questionnaire asked about current DPP-4 prescribing and whether the meeting changed choice, and that representatives “poured into” the room at the end to hand out prescribing information.
• Lilly stated the meeting was promotional with respect to Trajenta but mainly educational overall; it refuted that Byetta was promoted (exenatide mentioned only briefly and without brand name).
• Lilly stated a promotional stand was present in a separate room during lunch/registration and breaks; representatives did not enter the main meeting room.
• Invitations/ads stated the meetings were developed “in conjunction with, and sponsored by” the companies; most formats linked to prescribing information for linagliptin. The Panel noted one flyer format did not include prescribing information (though no allegation was made on that point).

Outcome

• No breach of Clause 19.1: the Panel considered the meeting had clear educational content.
• No breach of Clause 19.3: sponsorship was considered disclosed on invitations and slides.
• No breach of Clause 12.1: the Panel did not consider the promotional nature was disguised, given the impression created by the invitations.
• No breach of Clause 9.1: no failure to maintain high standards was found.
• The Panel nevertheless expressed a view (not part of the complaint) that prescribing information for Byetta (or a link) ought to have been included on all materials, and that Jentadueto prescribing information should have appeared on invitations (not only in presentations).

Clauses cited

• Clause 9.1
• Clause 12.1
• Clause 19.1
• Clause 19.3

Sanctions

• None (No breach case).
• Additional sanctions: Not stated.

Why this matters

• “Education vs promotion” is judged on overall impression (invite wording, sponsor prominence, agenda, content balance, and on-the-day set-up).
• Even where a company believes an event is clearly promotional, ambiguity in invitations (e.g., who “we” is, programme committee status) can trigger complaints and scrutiny.
• Panels may flag uncomplained issues (here: prescribing information expectations for all promoted products), creating forward-looking compliance risk.

Where teams slip up

• Invitations that look “independent” (publisher branding, programme committee photos) while sponsor involvement is not explained clearly enough.
• Multiple invitation formats where not all versions stand alone (e.g., a flyer missing prescribing information/link).
• Questionnaires that ask about current/future prescribing without clear rationale, optionality, and appropriate governance.
• On-the-day logistics (stands, rep presence, handouts) that can be perceived as “sales activity” if not tightly controlled and documented.

Control that would have prevented it

• A single, locked “master invite pack” with mandatory elements and a check that every channel/version is compliant and can stand alone.
• Clear statement on invites: sponsor role, whether content is promotional, and who the programme committee/publisher is (and in what capacity).
• Documented meeting plan covering rep access to rooms, what materials can be distributed where/when, and who collects evaluations.